Time	Speaker	Title
13:00 – 13:10	Welcome and Introduction by Professor Serge Cremers & Professor Peter Ferdinandy
13:10 – 13:35	Dr Angela Chiew	Management of serotonin syndrome (toxicity)
14:00 – 14:25	Professor Andreas Papapetropoulos	Novel drugs approved by the EMA, the FDA and the MHRA in 2024
14:25 – 14:50	Dr Lan Gao	Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier
14:50 – 15:15	Speaker TBC	Talk Title TBC
15:15 – 15:35	All Speakers	Open Panel Discussion
15:35 – 15:45	Closing Remarks by Professor Serge Cremers & Professor Peter Ferdinandy

Professor Andreas Papapetropoulos

Speaker: Professor Andreas Papapetropoulos

Talk title: Novel drugs approved by the EMA, the FDA and the MHRA in 2024

Biography: Andreas Papapetropoulos holds a bachelor’s degree in Pharmacy and a PhD in Pharmacology. He is currently Professor of Pharmacology at the National and Kapodistrian University of Athens and Affiliated Investigator at the Biomedical Research Foundation of the Academy of Athens, Greece. He is a fellow of the BPS and the AHA and a member of the Editorial Board of the BJP, JPET and ATVB. He has served as a National Delegate at the European Medicines Agency. He has been elected as Secretary General of EPHAR for 2016-2020. Andreas Papapetropoulos has studied the regulation, the physiological functions and the contribution of the nitric oxide/cGMP pathway to disease initiation and progression. More recently, he shifted the focus of his research to the physiology and pharmacology of hydrogen sulfide in the cardiovascular system. He has published 140 papers in peer-reviewed journals that have received >14,500 citations.

---

Other Speakers include: 

1. Dr Angela Chiew
2. Dr Lan Gao
3. Speaker TBC